The Company's core preservation technology produces an acellular tissue matrix, which retains the essential biochemical and structural components necessary for normal tissue regeneration. The Company also is developing several additional products, including small diameter vascular grafts as an alternative to autografted blood vessels, orthopedic applications of its acellular tissue matrix, and ThromboSol, a formulation for extended storage of platelets.
Revenues reflect the launch of two new products and increased funded research grant revenues.
Lower loss was partially offset by costs associated with the expansion of tissue processing capacity. Market Guide offers more in-depth Company Research , Stock Screening , and Hottest Stocks and Industries on over 10,000 U.S. Equities. All Rights Reserved. Privacy Policy - Terms of Service Company information Copyright Market Guide . Data and information is provided for informational purposes only, and is not intended for trading purposes.